Belgium
· Delayed Price · Currency is EUR Celyad Oncology Statistics
Total Valuation
Celyad Oncology has a market cap or net worth of EUR 9.90 million. The enterprise value is 3.96 million.
| Market Cap | 9.90M |
| Enterprise Value | 3.96M |
Important Dates
The next estimated earnings date is Friday, September 20, 2024.
| Earnings Date | Sep 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Celyad Oncology has 41.43 million shares outstanding.
| Shares Outstanding | 41.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 0.18% |
| Float | 14.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 60.28 |
| PB Ratio | 1.57 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.47 |
| EV / Sales | 38.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.25 |
Financial Position
The company has a current ratio of 3.79, with a Debt / Equity ratio of 16.78.
| Current Ratio | 3.79 |
| Quick Ratio | 3.34 |
| Debt / Equity | 16.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -116.00 |
Financial Efficiency
Return on equity (ROE) is -159.08% and return on invested capital (ROIC) is -99.63%.
| Return on Equity (ROE) | -159.08% |
| Return on Assets (ROA) | -33.03% |
| Return on Capital (ROIC) | -99.63% |
| Revenue Per Employee | 5,667 |
| Profits Per Employee | -469,333 |
| Employee Count | 19 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.36% in the last 52 weeks. The beta is 1.51, so Celyad Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -77.36% |
| 50-Day Moving Average | 0.26 |
| 200-Day Moving Average | 0.33 |
| Relative Strength Index (RSI) | 44.23 |
| Average Volume (20 Days) | 17,109 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celyad Oncology had revenue of EUR 102,000 and -8.45 million in losses. Loss per share was -0.33.
| Revenue | 102,000 |
| Gross Profit | 33,000 |
| Operating Income | -9.51M |
| Pretax Income | -8.51M |
| Net Income | -8.45M |
| EBITDA | -9.00M |
| EBIT | -9.51M |
| Loss Per Share | -0.33 |
Balance Sheet
The company has 7.00 million in cash and 1.06 million in debt, giving a net cash position of 5.95 million or 0.14 per share.
| Cash & Cash Equivalents | 7.00M |
| Total Debt | 1.06M |
| Net Cash | 5.95M |
| Net Cash Per Share | 0.14 |
| Equity (Book Value) | 6.30M |
| Book Value Per Share | 0.15 |
| Working Capital | 8.19M |
Cash Flow
In the last 12 months, operating cash flow was -15.20 million and capital expenditures -899,000, giving a free cash flow of -16.10 million.
| Operating Cash Flow | -15.20M |
| Capital Expenditures | -899,000 |
| Free Cash Flow | -16.10M |
| FCF Per Share | -0.39 |
Margins
| Gross Margin | 32.35% |
| Operating Margin | -9,325.49% |
| Pretax Margin | -8,344.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -15,785.29% |
Dividends & Yields
Celyad Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -137.42% |
| FCF Yield | -162.61% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |